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Endocytosed protein antigens are believed to be fragmented in what appears to be a balance 
between proteolysis and MHC-mediated epitope protection, and the resulting peptide-MHC 
complexes are transported to the surface of the antigen-presenting cells (APC) and presented to 
T cells. The events that lead to antigenic peptide generation and the compartments where anti- 
gen processing takes place remains somewhat enigmatic. The importance of intracellular anti- 
gen processing has been well established; however, it is unclear whether additional processing 
occurs at the APC surface. To follow antigen processing, we have identified a pair ofT cell hy- 
bridomas that recognize a long vs. a short version of the same epitope. We have used prefixed 
APC and various protease inhibitors to demonstate that the APC surface has a considerable po- 
tential  for antigen  processing.  Specific  antibodies  further  identified  the  exopeptidase Ami- 
nopeptidase N  (APN, CD13) as one of the enzymes involved in the observed cell-surface anti- 
gen processing.  The NH2-terminal end of the  longer peptide  could,  even while bound  to 
major histocompatibility complex (MHC) class II molecules, be digested by APN  with dra- 
matic consequences for T  cell antigen recognition. This could be demonstrated both in cell- 
free systems using purified reagents and in cellular systems.  Thus, MHC class II and APN may 
act in concert to generate the final T  cell epitopes. 
T 
h  cells  recognize  protein  antigens  presented  in  the 
context of MHC class II molecules. The bulk of evi- 
dence suggests that protein antigens before presentation are 
internalized, transported to an acidic compartment, and par- 
tially  degraded (reviewed in reference 1). Some of the re- 
sulting peptides are bound to class I1 molecules (2, 3), pro- 
tected against  further degradation (4, 5), and transported to 
the APC surface for Th cell scrutiny. Implicidy, antigen pro- 
cessing is viewed as an intracellular event, and tittle atten- 
tion is currently paid to the cell surface as an auxiliary com- 
partment for antigen processing. We have previously found 
that inhibitors ofproteolytic enzymes could alter the speci- 
ficity and sensitivity of the of antigenic peptide presentation 
by prefixed APC (6). Since prefixed APC are unable to in- 
ternalize antigen and thus to perform intracellular antigen 
processing,  these results suggested that some antigen pro- 
cessing can occur at the cell surface. However, we were at that 
time unable to establish the exact identity and localization 
of the enzyme(s) involved. In this paper, we have used pre- 
fixed APCs and a pair of Ak-restricted T  cell hybridomas spe- 
cific for hen egg lysozyme (HEL)46-tt~ and  HELs0-61~, 
respectively, to assess cell surface antigen processing and to 
identify one  of the  enzymes involved.  The APC  surface 
was  able  to  perform  considerable  antigen  processing.  A 
careful analysis of the contribution of the various groups of 
proteases and a panel of mAbs  allowed us  to identify the 
ectopeptidase  aminopeptidase  N  (APN, 1 also  known  as 
CD13), as one of the enzymes involved in cell-surface anti- 
gen processing. We have demonstrated that APN can trim 
amino-terminal ends ofpeptides that protrude out ofM HC 
class II, and we have also demonstrated that this has signifi- 
cant effects on T  cell stimulation and specificity. In support 
of this scenario, APN has been previously found to be ex- 
pressed on MHC class II-bearing APC  (7), and  the NH2- 
terminal sequence pattern of MHC class II bound  peptides 
is compatible with the frequent involvement of APN in in 
vivo antigen processing (8, 9). 
Materials and Methods 
Cells.  The H-2  k B lymphoma cell line  CH12 (10) was used 
for antigen presentation; it was grown in vitro (37~  5% COz) in 
ILPMI 1640 containing 5% FCS. The H--2  t B lymphoma cell line 
1Abbreviations used in this paper:/kPN, anninopeptidase N; cPl, complete 
protease inhibitor  cocktail; HEL,  hen egg iysosome. 
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and produced in AKR mice. 
The  HEL specific, Ak-restricted T  cell hybridomas 3A9 and 
kLy17.5  were grown in vitro (37~  5%  CO2)  in RPMI  1640 
containing 5%  FCS. The  inverse response pattern of these two 
hybridomas to  NH2-terminally truncated HEL46_61(Y )  served as 
an important control throughout these experiments. 
Antibodies.  The rat mAbs R3-63  (IgG2a) and 2M-7  (IgG2a) 
both  block  mouse  APN  enzyme  activity.  R3-242  (IgG1, 
09531D;  Pharmingen,  San Diego, CA) and R4-68  (IgG1) bind 
to a common site on APN without blocking its activity. R3-134 
(IgG1) binds to another site on APN without blocking its activ- 
ity. R3-152  (IgG2a) is not specific for APN, and is included for 
control purposes. These antibodies have all been described previ- 
ously (7). They were generated as ascites in nude mice and puri- 
fied by affinity chromatography using the mouse anti-rat K light 
chain IgG antibody RG7/9.1  (TIB 169; American Type Culture 
Collection, Rockville, MD). 
Peptides.  Peptides  were  synthesized by  conventional  Fmoc 
strategy on a Ramps synthesizer (DuPont, Wilmington, DE),  as 
previously described (12).  After completion of the synthesis ac- 
cording to the sequence, the peptides were deprotected, cleaved 
from the resin, and finally ether precipitated. The HEL46_61(v  ) se- 
quence is in single letter code: NTDGSTDYGILQINSR(Y). 
Antigen Presentation.  In most experiments, peptides were pre- 
sented by prefixed APCs.  The  APCs,  CH12,  were  fixed with 
0.05%  glutaraldehyde for 30 s at room temperature, followed by 
three washes in PBS containing 75 mM L-glycine (pH 7), resus- 
pended at 60 106/ml in PBS (pH 7) containing a protease inhibi- 
tor cocktail (see below), pulsed (2 h at 37~  with a dose range of 
synthetic peptide, washed extensively, and resuspended in culture 
media. 2  ￿  105 T  hybridoma cells were incubated with 2  ￿  10  s 
pulsed APCs for 24 h at 37~  in a total of 250 ml. 
In a few experiments, purified peptide-MHC complexes were 
coated onto latex particles and offered to the T  cell hybridomas 
(13,  14).  Briefly, 8  ￿  107/ml  sulphonated latex particles (5.12 
mm; Interracial Dynamics, Portland, OR) were incubated (over- 
night  at  4~  with  0.5  mM  peptide-MHC  complexes.  The 
coated latex beads were blocked (1% BSA in PBS for 2 h at 4~ 
washed, and resuspended in tissue culture media. FACS  ~ analysis 
(Becton Dickinson & Co., Inc., Mountain View, CA) confirmed 
that equal numbers of A k molecules were coated onto the beads 
in the various experimental groups. 2  ￿  105 T  hybridoma ceils 
x,cere incubated with 5 ￿  106 latex beads for 24 h at 37~  in a to- 
tal of 250 ml. 
The IL-2 content of the hybridoma supernatants were tested 
by  their  ability to  support  [3H]thymidine  incorporation  into 
4,000  HT-2 or by visual scoring according to Kappler et al. (15). 
Inhib(tion of Protease Activity.  The prefixed CH12s were pulsed 
with peptide in the presence of various mixtures of protease in- 
hibitors. The  chemical inhibitors included PMSF (used at a final 
concentration  of 1 raM), EDTA  (8  raM),  1.10  phenanthroline 
(1.2 raM), pepstatin A  (69 raM), Na-p-tosyl-L-lysine chlorome- 
thyl ketone (TL CK, 128 raM), Na-p-tosyl-L-phenyialani.n_e  chlo- 
romethyl  ketone  (TPCK,  135  raM),  and  N-ethylmaleimide 
(NEM, 1 raM). The protease inhibitors were crudely grouped as: 
PMSF,  TLCK and  TPCK,  serine, proteinase inhibitors; NEM, 
cysteine proteinase inhibitor; EDTA  and  1.10  phenanthroline, 
metallo-proteinase inhibitors; and pepstatin A, aspartic Acid pro- 
teinase inhibitor. A  cocktail containing all the proteases was de- 
noted  "complete  protease  inhibitor"  cocktail  (or  cPI),  and  a 
cocktail containing all but the metallo-protease inhibitors was de- 
noted  API.  Note  that  EDTA/1.10  phenanthroline  under  the 
conditions used here irreversibly inhibits APN, since this enzyme 
can only be reactivated by an equimolar concentration of Zn  2+, 
Cu  2+, Co  2+, or Ni  2+ (16), none of which are present under tissue 
culture  conditions.  In  contrast,  reversible  inhibition  of APN 
could be achieved by manipulating the pH of the reaction buffers. 
Experiments  with  affinity-purified APN  established that  APN 
was inactivated at pH 5.0, but subsequently could be reactivated 
at pH 7 (data not shown). 
For a more detailed identification of the enzymes involved, the 
chemical metallo-protease inhibitors were in some  experiments 
substituted with rat anti-mouse APN antibodies capable of  specif- 
ically blocking APN function  (this amounts to adding the rele- 
vant antibodies to API). 
APN  Treatment of Purified Peptide-MHC  Class II Complexes. 
A  k was affinity purified from lysates of AKTB-lb using the mono- 
clonal anti-A  k antibody 10-3.6.2  (TIB 92; ATCC), as previously 
described (17).  Mouse APN was affinity purified from homoge- 
nized mouse  kidneys using the  rat monoclonal anti-APN anti- 
body R3-63,  as  previously described  (7).  Complexes  between 
320 mM HEL46_61(Y ) and 10 mM A k were generated at pH 4.4 in 
the presence of API and purified by spun column chromatogra- 
phy (18). 5 mM HELa6_61(y)-A  k complexes were digested (24 h at 
37~  with 1 mM affinity-purified mouse APN (5, 7,  19). These 
complexes were coated onto latex beads and tested for their abil- 
ity to stimulate the T  cell hybridomas as described above. 
Results and Discussion 
Two  HEL-specific, mouse  class  II  AL-restricted T  cell 
hybridomas, 3A9 and kLy17.5, were used to study cell-sur- 
face  antigen  processing  by  the  H-2  k  B  cell  lymphoma, 
CH12.  To  prevent  antigen  uptake  and  intracellular pro- 
cessing, the APCs were fixed with glutaraldehyde (20). To 
examine  cell-surface processing,  the  prefixed APCs  were 
pulsed  with  HEL46_61(Y  )  in  the  absence  or  presence  of a 
complete  protease  inhibitor  cocktail  (cPI)  inhibiting  the 
four known  groups of proteinases (6).  Pulsing in the pres- 
ence  of the  cPI enhanced presentation to  the 3A9  (Fig.  1 
A), whereas it blocked presentation to kLy17.5  (Fig.  1 B). 
This  suggests that functionally relevant antigen processing 
can  occur at the  cell surface and  supports  the notion that 
3A9 recognizes the intact HEL46_61(y ) peptide (21). In con- 
trast,  kLy17.5  recognizes a  truncation  of HEL46_61(Y  ).  To 
identify  the  optimal  epitopes,  a  series  of  NH2-terminal 
truncations  of the  HEL46_61(v )  epitope  was  tested  in  the 
presence  of the  cPI.  The  optimal  epitope  for  3A9  was 
found  to  be  17-mer  HEL46_61(Y  )  (Fig.  1  C),  whereas  the 
optimal  epitope  for  kLy17.5  was  the  13-mer  HELs0_61(v  ) 
(Fig.  1  D).  COOH-terminal  truncations were  not  exam- 
ined,  since tryptophan  in  position 62  (represented in  our 
peptides by  tyrosine)  is  known  to  delineate the  COOH- 
temlinal part of the epitope (22, 23).  All the following ex- 
periments examined the presentation ofHEL46_61(y  ) to 3A9 
and kLy17.5, and they exploited the reciprocal effect of the 
various  protease  inhibitor  mixtures  upon  these  two  re- 
sponses.  This  is  an  important  control,  since  it  effectively 
rules out that the protease inhibitors are acting on general 
T  cell response mechanism(s).  Furthermore, admixture ex- 
periments where APCs that had been pulsed with peptide 
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Figure  I.  Cell-surface antigen processing af- 
fects T  cell responses both quantitatively and 
qualitatively. (A and B) CH12 antigen-present- 
ing cells were  prefixed in  glutaraldehyde and 
pulsed with HEL46_61~) in the presence (O) or 
absence (￿9  of a  complete protease inhibitor 
cocktail  (cP!).  Two  HEL46_61-specific,  A  k- 
restricted T cell hybridomas, 3A9 and kLy17.5, 
were used to assess the stimulatory capacity of 
the  APCs. To define the  optimal epitopes of 
3A9 (C) and kLy17.5 (D), prefixed CH12 were 
pulsed  with  graded doses of  NH2-terminal 
truncations of HEL46_61(Y ) in the presence of 
cPI (HEL46_61  ~, O; HEL47_61~, l; HEL48_61(Y), 
[~; HEL49_61fY), A; HELso_61~v/, A; HEL51_~ICv), 
O; HEL52_61(v),  ~. Also shown is HEL46_6ffv) in 
the absence ofcPI (￿9 
in the absence of cPI were mixed with APCs that had been 
pulsed  with  cPI  in  the  absence  of peptide,  demonstrated 
that cPI was not carried over in amounts sufficient to affect 
the  read-out  system through  toxic  effects,  or through  ef- 
fects  upon  antigen  presentation  and/or  T  cell  responsive- 
ness during the read-out (data not shown). 
The  contributions  of the  different  proteinases  were  ex- 
amined by two complementary approaches. First, groups of 
proteinase inhibitors were deleted one by one from the cPI 
and the  modified inhibitor  cocktail was tested on cell-sur- 
face antigen processing of HEL46_6100.  Metallo-proteinases 
were  by  far the  most  important  group  of proteinases  in- 
volved,  since  deleting  the  corresponding  inhibitors  from 
the  cPI  allowed  significant  processing  of HEL46_61(Y),  as 
shown  by  decreased  presentation  to  3A9  and  enhanced 
presentation  to kLy17.5  (both  compared to  cPI,  Fig.  2, A 
and B). Deleting the cysteine inhibitors from the cPI had a 
minor  effect,  whereas  deleting  the  serine  or  aspartic  acid 
inhibitors  had  no  effect.  Second,  groups  of proteinase  in- 
hibitors were  tested  alone,  confirming  the  dominant  con- 
tribution of metallo-proteinases, since the corresponding in- 
hibitors on their own prevented processing of HEL46_61(Y), as 
shown  by enhanced  presentation  to  3A9  and  blocking  of 
presentation to kLy17.5 (both compared to no PI, Fig. 2, C 
and D).  An exact identification  of the  enzyme(s) responsi- 
ble was, however, impossible because of the limited speci- 
ficity of the chemical inhibitors. 
APN  is  an  obvious  candidate,  since  it  is  a  membrane- 
bound  metallo-exopeptidase;  it has been found  on  class II 
beating APC's of the mouse immune system (7), and it could 
account  for  the  conversion  of HEL46_61(Y )  to  HELso_61(y  ). 
One of us (A. Stryhn)  has recently generated a panel of rat 
monoclonal anti-mouse APN antibodies and crudely mapped 
APN  epitopes  (7).  Antibodies  specific  for  different  APN 
epitopes were selected for further study. Importantly, some 
of these  mAbs  are potent  inhibitors  of APN  activity,  and 
compared  to  the  chemical  protease  inhibitors,  such  anti- 
body-mediated inhibition  is quite specific. Substituting  the 
chemical metallo-proteinase inhibitors of the cPI with satu- 
rating concentrations  of the  different relevant or irrelevant 
mAbs showed that APN is one of the important enzymes in- 
volved  in  cell-surface  antigen  processing  of  HEL46_61(Y  ) 
(Fig.  2,  E  and  F).  The  two  anti-APN  antibodies,  R.3-63 
(Fig. 2, E  and F) and 2M-7  (data not shown), which inhibit 
APN activity (7), could substitute most of the activity of the 
metallo-proteinase  inhibitors,  whereas  the  noninhibitory 
anti-APN  antibody,  R3-134,  and  the  irrelevant  antibody, 
R3-152,  had  no  effect  (Fig.  2,  E  and  it).  The  inhibitory 
anti-APN  antibodies  had  the  same  effect  as  the  chemical 
inhibitors  on the stimulation and peptide size preference of 
the two T  cell hybridomas,  arguing against inadvertent  ef- 
fects on something else than APN,  and suggesting that the 
effect is caused by the enzyme activity of the APN. Further- 
more,  the  effects  of the  protease  inhibitors  depended  on 
the  size  of  the  stimulating  peptide  (e.g.,  cPI  blocked 
HEL46_6100  stimulation,  but enhanced  HELs0_61fv  ) stimula- 
tion  of kLyl7.5),  arguing  against  APN  acting  on  some 
other moiety than peptide. 
Surprisingly,  two  antibodies,  R.3-242  (Fig.  2,  E  and  F) 
and R4-68  (data not shown), which are specific for a com- 
mon noncatalytic  site on the APN  (7), were potent inhibi- 
tors  of HEL46_61(Y  ) surface processing,  suggesting  that  the 
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Figure  2.  APN is involved in cell-surface processing 
of HEL46_6t(v  ). Prefixed CH12 were pulsed with increas- 
ing doses of HEI46_6~(v  ) in the presence of various modi- 
fications of the protease inhibitor cocktail, and were used 
to stimulate 3A9 or kLy17.5. (A and B) The cPI was 
modified by deletion of protease inhibitors group  by 
group: cPI (O), cPI with serine proteinase inhibitors de- 
leted (A), cPI with cysteine proteinase inhibitors deleted 
(~),  cPI with metallo-proteinase inhihitors deleted (I), 
cP1 with aspartic acid proteinase inhibitors deleted (U]), 
and no PI (O). (C and D) The protease inhibitors were 
also tested groupwise: cPI (0), serine proteinase inhibi- 
tors alone (A), cysteine proteinase inhibitors alone (~), 
metallo-proteinase inhibitors  alone (l),  aspartic acid 
proteinase inhibitors alone ([2]), and no PI (O). (E and r~ 
The  metallo-proteinase inhibitors,  EDTA  and  1.10 
phenanthroline, were deleted from the cPI to generate a 
cocktail denoted API. The API was supplemented with 3 
n~Vl of various rat anti-mouse APN antibodies: R3-63 
([]),  R.3-242 (O), 1<3-134 (A), R3-152  (A). Also 
shown are cPI (0), ApI (m), and no PI (O). 
involvement  of APN  exceeds  mere  proteolysis.  We  rea- 
soned that these antibodies might block the access of APN 
to the MHC, implying that APN degrades peptides already 
bound  to  the  MHC.  To  address  this  possibility  directly, 
preformed  and  purified  HEL46_61(y)-A  k  complexes  were 
digested  by  afffinity-purified  APN  (5),  coated  onto  latex 
particles  (13,  14),  and  offered to  3A9 and  kLy17.5.  APN 
treatment  consistently  reduced  the  capacity  to  stimulate 
3A9 and improved the ability to stimulate kLy17.5 (Fig. 3 A). 
To corroborate this finding,  a cellular experiment was de- 
vised. Prefixed APC were pulsed (2 h at room temperature) 
with  HEL46_6~(y  ) at pH  5,  which  allows A k binding  (19), 
but reversibly inhibits APN activity (data not shown). Sub- 
sequently,  the  cells  were  washed  and  incubated  (2  h  at 
37~  at pH  7.0,  which reactivates APN,  and R3-63  (in- 
hibitor of APN activity)  or R.3-152  (irrelevant)  antibodies 
were added to determine the contribution of APN to anti- 
gen processing during this phase of the experiment.  Indeed, 
APN  strongly  decreased  3A9  responses  and  strongly  in- 
creased kLy17.5 responses (Fig. 3 B).  To exclude the possi- 
bility  that  the  processing  of HEL46_61(u  ) occurred  outside 
the A k, followed by exchange into the A k, a peptide  capa- 
ble of blocking A k binding, but not APN activity (data not 
shown), was added to one set-up during APN reactivation. 
The  inability  of the  Ak-blocking peptide  to  prevent  the 
generation of the kLy17.5 stimulatory moiety excluded the 
possibility that peptide binding to A k took place after APN 
digestion.  Thus, we conclude that APN-mediated process- 
ing took place while the HEL46_61(Y  ) was bound to A k. 
Our  experimental  design  included  a  step  of mild  alde- 
hyde  fixation  intended  to  prevent  transport  across  the 
membrane and thereby intracellular antigen processing.  In 
general,  prefixed  cells  are unable  to present  intact protein 
antigens  (24, 25),  supporting the notion of a dominant in- 
tracellular  contribution  to  in  vivo  antigen  processing.  As 
demonstrated  here,  however,  functionally  significant pro- 
cessing  of peptide  antigens  can  occur  after  fixation.  We 
pulsed the prefixed APCs in a PBS-based buffer (i.e., in the 
absence  of serum  proteases),  suggesting  that  the  observed 
processing took place at the cell membrane, not in the me- 
dia.  Note,  however,  that  this  does  not  exclude  that pro- 
cessing under physiological conditions can occur in serum. 
Indeed serum proteases,  such  as  angiotensin-l-converting 
enzyme,  have  been  implicated  in  antigen  processing  (26, 
27). Most importantly, we further pinpointed the auxiliary 
peptide  processing event to the protruding  ends  of MHC 
class  II-bound  peptides,  and  implicated  the  membrane- 
bound exopeptidase APN (Fig. 3, A  and B). Thus, we sug- 
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Figure  3.  APN  can  process HEL46_61(x  9 while  it  is 
bound to A  k. (.,4) In a biochemical  approach, 5 mM puri- 
fied HEL46_6100/A  k complexes were incubated  in the pres- 
ence (solid bars) or absence (hatched bars) of I mM purified 
APN for 24 h at 37~  in PBS containing API (see Fig. 2) 
and 0.1% NP-40. Digested complexes were coated onto 
latex particles, which subsequently were incubated with 
3A9 or kLy17.5. (B) In a cellular  approach, prefixed APCs 
were pulsed in the presence of API with HEL46_61(v  ) for 
2 h at room temperature. Pulsing  was done at pH 5, which 
reversibly blocks APN  activity. Subsequently, the  cells 
were washed to remove unbound peptide, and the cells 
were exposed to a "postpulse" incubation in the presence 
of ApI for 2 h at 37~  The postpulse incubation was con- 
ducted at pH 7.0, which reactivates the APN and allows it 
to digest the peptide--MHC class II complexes that were 
generated in the previous step. To assess the effect of the 
reactivated APN, the ApI was supplemented  with the rat 
mAb R3-63  ([]), which is a strong inhibitor of mouse 
APN, or with the irrelevant isotype-matched mAb K3- 
152 (&). In one set-up, 50 mM of the Ak-binding  peptide 
PPANDQGNRTTPSY (A) was added to the API to ex- 
clude peptide exchange during the post-pulse. Also shown 
are the effects ofcPI (O), API (I), or no PI (C)) during the 
pulse and postpulse incubations. 
gest that the APC surface can modify or trim MHC  class 
II-bound  peptides should intracellular processing fail to gen- 
erate peptides that can be contained within the MHC class 
II-binding  groove. Does the latter occur? Antigen degrada- 
tion appears to be a stochastic process yielding peptides of 
heterogeneous sizes.  Experimentally, it  has  been demon- 
strated that MHC  class II-bound peptides are from 10-35 
amino acids long (23,  28,  29)  to  intact proteins  (30-32). 
They are  known to  have  "ragged"  ends  (23,  28,  29,  33), 
and some of these ragged ends are likely to protrude out of 
the  binding groove  and  be  susceptible  to  exopeptidases 
(34).  The  extent of APN-mediated trimming depends in 
part on the specificity of the APN (35, 36), in part on the 
accessibility of the MHC  groove. It may even involve the 
interaction of APN with class II during antigen trimming, 
as indicated here by the effect ofmAbs R3-242 and R4-68. 
Thus, antigen processing and display cannot be viewed as 
two  sequential events, but rather as a continuous series of 
interdependent  events.  In  this  particular  case,  APN  is 
stopped  either  by  the  occurrence  of prolines within the 
protruding NH2-terminal  end  or  spatially by  the  MHC 
class  II  itself.  The  frequent occurrence of prolines at  the 
i+ 1 position of class II-bound peptides would indicate that 
a great many peptide-class II complexes indeed have been 
visited in vivo by an exopeptidase such as APN  (8,  9).  In 
this  context,  the  correlation between  MHC  class  II  and 
APN  expression on APCs is particularly striking (7).  It is 
tempting  to  speculate  that  protruding  carboxy-terminals 
may  be  trimmed by  a  carboxy  peptidase  (or  a  carboxy- 
dipeptidase  such  as  angiotensin-l-converting enzyme,  as 
demonstrated for MHC  class I-restricted T  cell responses; 
26, 27, 37), with similar powerful effects on the sensitivity 
and specificity of T  helper cell responses,  as demonstrated 
here for APN.  Finally, it is also tempting to speculate that 
"outsize" peptides, albeit not favored for binding to MHC 
class I, might be susceptible to trimming. 
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